← board
RPRX
distress 3/10 · well-funded / low risk$58.710%today0% from 52w high
Revenue
$631M
Liquidity
$586M
Runway
—
Shares 1y
+6%
Price & events
+47.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.0%
1D
+0.3%
1W
+6.1%
1M
+18.8%
3M
+46.7%
6M
+66.5%
1Y
+116.7%
2Y
+63.7%
5Y
+42.0%
All
Overview
- Market Cap
- $22.79B
- Enterprise Value
- $30.78B
- Volume
- 116.19K
- 52 Week Range
- $34.90 – $58.72
- Total Shares
- 388.13M
- Float Shares
- 413.50M
- Short %
- 2.85%
- % Held by Insiders
- 6.51%
- % Held by Institutions
- 86.04%
- RVOL
- 0.04x
- Beta
- 0.42
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-01-10partnershipRoyalty Pharma Holdings acquires all equity interests of RP LLC from sellers for cash and shares, and assumes $380M term loan.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $60 (+2% upside) · 9 analysts
- 2026-07-13TD CowenBuy
- 2026-05-07CitigroupBuy
- 2026-05-07JP MorganOverweight
- 2026-04-21UBSBuy
- 2026-04-10Morgan StanleyOverweight
- 2026-01-30UBSNeutral → Buy
Competitors
- none identified
Recent news
- 2026-07-23Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma - marketscreener.com
- 2026-07-23Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
- 2026-07-23177,500 Shares in Royalty Pharma PLC $RPRX Acquired by Andra AP fonden - MarketBeat
- 2026-07-22Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com UK
- 2026-07-22Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com Nigeria
- 2026-07-22Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - marketscreener.com
- 2026-07-22Royalty Pharma deal includes $125M upfront for heart antibody - Stock Titan
- 2026-07-22Royalty Pharma PLC $RPRX Shares Bought by Swiss National Bank - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.